Novartis AG (NYSE:NVS) Shares Sold by Traveka Wealth LLC

Traveka Wealth LLC trimmed its stake in shares of Novartis AG (NYSE:NVS) by 6.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,304 shares of the company’s stock after selling 221 shares during the period. Traveka Wealth LLC’s holdings in Novartis were worth $321,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Steigerwald Gordon & Koch Inc. increased its position in shares of Novartis by 4.8% in the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock valued at $241,000 after purchasing an additional 95 shares during the last quarter. Centaurus Financial Inc. grew its stake in shares of Novartis by 1.7% during the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock worth $659,000 after purchasing an additional 98 shares in the last quarter. FLC Capital Advisors increased its holdings in Novartis by 4.4% in the third quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock valued at $272,000 after buying an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC raised its stake in Novartis by 2.3% in the third quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock valued at $509,000 after buying an additional 100 shares in the last quarter. Finally, Allen Wealth Management LLC lifted its holdings in Novartis by 1.8% during the 3rd quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock worth $666,000 after buying an additional 100 shares during the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Novartis Stock Up 0.1 %

Shares of NYSE:NVS opened at $99.20 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The stock has a market cap of $202.76 billion, a P/E ratio of 11.52, a P/E/G ratio of 1.49 and a beta of 0.57. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92. The firm has a fifty day moving average price of $101.33 and a 200 day moving average price of $109.24.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The firm had revenue of $12.82 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter in the previous year, the firm posted $1.74 EPS. Sell-side analysts predict that Novartis AG will post 7.65 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on NVS. BMO Capital Markets raised their target price on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Finally, Erste Group Bank restated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $121.50.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.